Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an 'Intention to grant' for the patent application covering the company's stem cell product XSTEM. Once the patent is approved, the stem cell product will be protected on the European market for at least another 18 years. BioStock has contacted Evy Lundgren-Åkerlund, CEO of Xintela, to find out more about XSTEM and the patent.

Read the full article here.

Attachments

  • Original document
  • Permalink

Disclaimer

Xintela AB published this content on 09 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 November 2020 15:57:07 UTC